Citadel Securities Maintains a 'Neutral' on Savient Pharmaceuticals (SVNT); Ilaris FDA Panel Rejection Removes Potential Krystexxa Adoption Overhang
Tweet
Share
E-mailGet Alerts SVNT Hot Sheet
Price: $40.05 --0%
Rating Summary:
2 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
2 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Citadel Securities maintains a 'Neutral' on Savient Pharmaceuticals (NASDAQ: SVNT)
Citadel analyst said, "We continue to anticipate a slow launch ramp for Krystexxa until 2Q12, at which point we believe the impact of a permanent J-code could cause a meaningful inflection in sales. We estimate U.S. Krystexxa revenues of $6.0MM in 2011 and $45.2MM in 2012. Additionally, we continue to anticipate approval of Krystexxa in the EU in early 2012, followed by a country-by-country launch in mid-2012. We believe SVNT will be able to meet U.S. and potential EU demand for Krystexxa based on the current single-source supply until a second manufacturer comes on-line."
For more ratings news on Savient Pharmaceuticals click here and for the rating history of Savient Pharmaceuticals click here.
Shares of Savient Pharmaceuticals closed at $6.87 yesterday.
Citadel analyst said, "We continue to anticipate a slow launch ramp for Krystexxa until 2Q12, at which point we believe the impact of a permanent J-code could cause a meaningful inflection in sales. We estimate U.S. Krystexxa revenues of $6.0MM in 2011 and $45.2MM in 2012. Additionally, we continue to anticipate approval of Krystexxa in the EU in early 2012, followed by a country-by-country launch in mid-2012. We believe SVNT will be able to meet U.S. and potential EU demand for Krystexxa based on the current single-source supply until a second manufacturer comes on-line."
For more ratings news on Savient Pharmaceuticals click here and for the rating history of Savient Pharmaceuticals click here.
Shares of Savient Pharmaceuticals closed at $6.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades IDP Education (IEL:AU) (IDPUF) to Hold
- Rubrik Inc (RBRK) PT Raised to $120 at Cantor Fitzgerald Into Q2 Earnings
- Hims and Hers (HIMS) PT Lowered to $35 at Barclays
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
